UNITED THERAPEUTICS Corp

Drug pipeline (4)

Asset	Stage	Revenue	Trials	Status
DINUTUXIMAB	approved	—	2	approved
Treprostinil	approved	—	7	approved
Treprostinil Diolamine	approved	—	6	approved
RALINEPAG	phase2	—	1	no active trials

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (74)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT00069511	phase2	unknown	2003-07-01	—	United Therapeutics	12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.
NCT01172496	phase1	completed	2010-08-01	2010-08-01	United Therapeutics	A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers
NCT01104870	phase2	completed	2010-04-01	2013-01-01	United Therapeutics	A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
NCT01934582	phase3	completed	2013-08-01	2013-11-01	United Therapeutics	A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
NCT03496623	phase3	terminated	2018-05-08	2022-10-13	United Therapeutics	A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

FDA applications (6)

Application

Type

Applicant

Products

BLA 125516

BLA

United Therapeutics Corporation

NDA 021272

NDA

UNITED THERAPEUTICS CORP

NDA 022387

NDA

UNITED THERAPEUTICS CORP

NDA 203496

NDA

UNITED THERAPEUTICS CORP

NDA 208276

NDA

UNITED THERAPEUTICS CORP